Pharmacokinetic model of unfractionated heparin during and after cardiopulmonary bypass in cardiac surgery

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Jia, Zaishen ^a   Tian, Ganzhong ^b   Ren, Yupeng ^b   Sun, Zhiquan ^a   Lu, Wei ^b   Hou, Xiaotong ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Pharmacokinetic model; Unfractionated heparin

Indexed keywords

HEPARIN; PROTAMINE SULFATE; PROTAMINE;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CHINESE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INFUSION; FEMALE; HEART SURGERY; HUMAN; MALE; MATHEMATICAL MODEL; MEASUREMENT ACCURACY; OBSERVATIONAL STUDY; POPULATION MODEL; POSTOPERATIVE PERIOD; PREDICTION; REBOUND; ADOLESCENT; BIOLOGICAL MODEL; COMPUTER SIMULATION; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; COMPUTER SIMULATION; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROTAMINES; YOUNG ADULT;

EID: 84924336710     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-015-0404-5     Document Type: Article

References (22)

1. Beaudet JM, Weyers A, Solakyildirim K, Yang B, Takieddin M, Mousa S, et al. Impact of autoclave sterilization on the activity and structure of formulated heparin. J Pharm Sci. 2011;100:3396-404.
2. Schulman S, Bijsterveld NR. Anticoagulants and their reversal. Transfus Med Rev. 2007;21:37-48.
3. Linhardt RJ. 2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity. J Med Chem. 2003;46:2551-64.
4. Teoh KH, Young E, Blackall MH, Roberts RS, Hirsh J. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg. 2004;128:211-9.
5. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest J. 2001;119:64S-94.
6. Kuczka K, Harder S, Picard-Willems B, Warnke A, Donath F, Bianchini P, et al. Biomarkers and Coagulation Tests for Assessing the Biosimilarity of a Generic Low-Molecular-Weight Heparin: Results of a Study in Healthy Subjects With Enoxaparin. J Clin Pharmacol. 2008;48:1189-96.
7. Blaise G. Heparin and protamine interaction. Can J Anaesth. 1998;45:1144-7.
8. Lowenstein E, Johnston WE, Lappas DG, D'Ambra MN, Schneider RC, Daggett WM, et al. Catastrophic pulmonary vasoconstriction associated with protamine reversal of heparin. Anesthesiology. 1983;59:470-2.
9. Butterworth J, Lin YA, Prielipp RC, Bennett J, Hammon JW, James RL. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass. Ann Thorac Surg. 2002;74:1589-95.
10. Hyun B, Pence R, Davila J, Butcher J, Custer R. Heparin rebound phenomenon in extracorporeal circulation. Surg Gynecol Obstet. 1962;115:191-8.
11. Gollub S. Heparin rebound in open heart surgery. Surg Gynecol Obstet. 1967;124:337.
12. Teoh K, Young E, Bradley C, Hirsh J. Heparin binding proteins. Contribution to heparin rebound after cardiopulmonary bypass. Circulation. 1993;88:II420-5.
13. Falkon L, Sáenz-Campos D, Antonijoan R, Martín S, Barbanoj M, Fontcuberta J. Bioavailability and pharmacokinetics of a new low molecular weight heparin (RO-11)-a three way cross-over study in healthy volunteers. Thromb Res. 1995;78:77-86.
14. Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin III. Thromb Res. 1977;10:399-410.
15. Beal S, Sheiner L. NONMEM Users Guides, 1989-98, Beal S, Sheiner L. Hanover, MD: GloboMax LLC. 1998.
16. Shore-Lesserson L, Gravlee GP. Anticoagulation for Cardiopulmonary bypass. In: Gravlee GP, Davis RF, Utley JR, editors. Cardiopulmonary bypass: principles and practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins. 2008. p. 472-501.
17. Brunet P, Simon N, Opris A, Faure V, Lorec-Penet A-M, Portugal H, et al. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. Am J Kidney Dis. 2008;51:789-95.
18. Farrell PC, Ward R, Schindhelm K, Gotch F. Precise anticoagulation for routine hemodialysis. J Lab Clin Med. 1978;92:164-76.
19. Gretler DD. Pharmacokinetic and pharmacodynamic properties of eptifabatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparin. Clin Ther. 2003;25:2564-74.
20. Ouseph R, Brier ME, Ward RA. Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses. Am J Kidney Dis. 2000;35:89-94.
21. Boneu B, Caranobe C, Cadroy Y, Dol F, Gabaig A-M, Dupouy D, et al. Pharmacokinetic studies of standard unfractionated heparin, and low molecular weight heparins in the rabbit. Semin Thromb Hemost. 1988;14(1):18.
22. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest J. 2004;126:188S-203.